|Bid||73.55 x 300|
|Ask||73.56 x 800|
|Day's Range||72.77 - 73.74|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.76|
|Earnings Date||Jul 26, 2017|
|Dividend & Yield||2.08 (2.90%)|
|1y Target Est||76.70|
Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA for its triple Vosevi combination of sofosbuvir, velpatasvir and voxilapreviri, designed to treat hepatitis C. So why does Leerink analyst Geoff Porges remain unimpressed with the biotech giant, even on the heels of agency approval? Porges believes in the competition arena, Gilead is ultimately "disadvantaged" when heading up against AbbVie's rival hepatitis C drug Maviret. Sidelined on Gilead's HCV prospects, the analyst rates a Hold on Gilead stock, with a price target of $74, which implies a slight upside from current levels.
Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.
AbbVie is likely to swipe significant hepatitis C drug share from Gilead Sciences with an eight-week regimen, an analyst said Wednesday.